Trial · NCT01694849
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (Visit 2 to Visit 8) | STARTED | GFT505 80mg | 93 | |
| Treatment Period (Visit 2 to Visit 8) | STARTED | GFT505 120mg | 90 | |
| Treatment Period (Visit 2 to Visit 8) | STARTED | Placebo | 92 | |
| Treatment Period (Visit 2 to Visit 8) | Randomized | GFT505 80mg | 93 | |
| Treatment Period (Visit 2 to Visit 8) | Randomized | GFT505 120mg | 90 | |
| Treatment Period (Visit 2 to Visit 8) | Randomized | Placebo | 92 | |
| Treatment Period (Visit 2 to Visit 8) | Randomised and Received Treatment (Full Analysis Set and Safety Set) | GFT505 80mg | 93 | |
| Treatment Period (Visit 2 to Visit 8) | Randomised and Received Treatment (Full Analysis Set and Safety Set) | GFT505 120mg | 89 | |
| Treatment Period (Visit 2 to Visit 8) | Randomised and Received Treatment (Full Analysis Set and Safety Set) | Placebo | 92 | |
| Treatment Period (Visit 2 to Visit 8) | Efficacy Evaluable Set | GFT505 80mg | 82 | |
| Treatment Period (Visit 2 to Visit 8) | Efficacy Evaluable Set | GFT505 120mg | 78 | |
| Treatment Period (Visit 2 to Visit 8) | Efficacy Evaluable Set | Placebo | 77 | |
| Treatment Period (Visit 2 to Visit 8) | COMPLETED | GFT505 80mg | 84 | |
| Treatment Period (Visit 2 to Visit 8) | COMPLETED | GFT505 120mg | 79 | |
| Treatment Period (Visit 2 to Visit 8) | COMPLETED | Placebo | 78 | |
| Treatment Period (Visit 2 to Visit 8) | NOT COMPLETED | GFT505 80mg | 9 | |
| Treatment Period (Visit 2 to Visit 8) | NOT COMPLETED | GFT505 120mg | 11 | |
| Treatment Period (Visit 2 to Visit 8) | NOT COMPLETED | Placebo | 14 | |
| Follow-up Period (to Visit 9) | STARTED | GFT505 80mg | 84 | |
| Follow-up Period (to Visit 9) | STARTED | GFT505 120mg | 79 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01694849/flow